Dianthus Therapeutics, Inc. (DNTH)
DNTH moved a median of +0.49% 30 minutes after news, and +1.22% by the close. How DNTH actually reacts to news — the realized, point-in-time move the market made, measured across 274 labeled events over the last three years with zero look-ahead.
DNTH’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.16% | 52% | 272 |
| 30-min | +0.49% | 59% | 272 |
| 60-min | +0.26% | 61% | 272 |
| to close | +1.22% | 58% | 268 |
| Middle 50% of DNTH reactions | -0.94% to +2.21% |
|---|---|
| Median reaction (30-min) | +0.49% |
| Measured reactions | 274 |
Half of all Dianthus Therapeutics, Inc. news events land between -0.94% and +2.21% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How DNTH reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 51 | -0.07% | 45% | -0.25% |
| Rating reiterations | 60 | -0.07% | 47% | -0.03% |
| Price-target raises | 25 | -0.09% | 40% | +1.10% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how DNTH ranks against every other measured name →
That’s how DNTH usually reacts — get an email when it moves on news →Email me when DNTH moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to DNTH's baseline. Nothing else.
Recent DNTH events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Dianthus Therapeutics Recognized Among Fortune’s 2026 Best Workplaces In BioPharma | Press release | GlobeNewswire | -0.10% | -4.72% | |
| Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.24% | -0.94% | |
| Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2026 AANEM Annual Meeting | Press release | GlobeNewswire | +0.00% | -0.28% | |
| Form S-3ASR Dianthus Therapeutics, | SEC filing · Form S-3ASR | SEC EDGAR | +1.03% | +0.54% | |
| Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.54% | +1.32% | |
| Dianthus Therapeutics to Participate in Three Investor Conferences During September | Press release | GlobeNewswire | -0.13% | +1.22% | |
| Dianthus Therapeutics Announces DNTH312, a First-In-Class, Next-Generation Bifunctional Fusion Protein Combining Claseprubart and TACI, for Severe Autoimmune Diseases | Press release | GlobeNewswire | -0.11% | +3.23% | |
| Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 2026 Financial Results | Press release | GlobeNewswire | +1.81% | +2.38% | |
| Form 10-Q Dianthus Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.81% | +2.38% | |
| Form 8-K Dianthus Therapeutics, For: Aug 04 | SEC filing · Form 8-K | SEC EDGAR | +1.81% | +2.38% | |
| Dianthus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4) | Press release | GlobeNewswire | -0.11% | +3.23% | |
| Dianthus Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(C)(4) | Press release | GlobeNewswire | +1.05% | -1.01% | |
| Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis | Press release | GlobeNewswire | +0.16% | -0.39% | |
| Form 8-K Dianthus Therapeutics, For: Jun 12 | SEC filing · Form 8-K | SEC EDGAR | +2.54% | +6.35% | |
| Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.38% | +3.06% | |
| Dianthus Therapeutics to Participate in Two Investor Conferences | Press release | GlobeNewswire | -1.90% | -1.37% | |
| Form 8-K Dianthus Therapeutics, For: May 21 | SEC filing · Form 8-K | SEC EDGAR | -0.62% | -0.82% | |
| Oorja Bio Launches as a Clinical-Stage Company to Develop Groundbreaking Therapies for Idiopathic Pulmonary Fibrosis (IPF) and Other Fibrotic Diseases | Press release | GlobeNewswire | -0.04% | +0.06% | |
| Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results | Press release | GlobeNewswire | -1.38% | -1.51% | |
| Form 10-Q Dianthus Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -1.38% | -1.51% | |
| Form 8-K Dianthus Therapeutics, For: May 05 | SEC filing · Form 8-K | SEC EDGAR | -1.38% | -1.51% | |
| LBL-047 Prioritized for Clinical Development in Sjögren's Disease, Systemic Lupus Erythematosus, and Dermatomyositis | Press release | GlobeNewswire | -1.38% | -1.51% | |
| Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -3.42% | +2.71% | |
| Form ARS Dianthus Therapeutics, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.84% | -2.42% | |
| Form DEF 14A Dianthus Therapeutics, For: May 21 | SEC filing · Form DEF | SEC EDGAR | -0.84% | -2.42% | |
| Form DEFA14A Dianthus Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | -0.84% | -2.42% | |
| Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.55% | +1.59% | |
| Form 8-K Dianthus Therapeutics, For: Mar 26 | SEC filing · Form 8-K | SEC EDGAR | +0.81% | +3.09% | |
| Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares | Press release | GlobeNewswire | +0.90% | -3.22% | |
| Form 8-K Dianthus Therapeutics, For: Mar 10 | SEC filing · Form 8-K | SEC EDGAR | -3.27% | -6.09% | |
| Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering | Press release | GlobeNewswire | -1.33% | -1.17% | |
| Form S-3MEF Dianthus Therapeutics, | SEC filing · Form S-3MEF | SEC EDGAR | -1.33% | -1.17% | |
| Dianthus Therapeutics Announces Early GO Decision Following Interim Responder Analysis in Phase 3 CAPTIVATE Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Press release | GlobeNewswire | +6.11% | +1.32% | |
| Dianthus Therapeutics Highlights Recent Business Achievements, Including GO Decision for Phase 3 CAPTIVATE CIDP Trial, and Reports Q4 and FY 2025 Financial Results | Press release | GlobeNewswire | +6.11% | +1.32% | |
| Dianthus Therapeutics, Inc. Announces Proposed $400 Million Underwritten Public Offering | Press release | GlobeNewswire | +0.22% | +7.20% | |
| Form 10-K Dianthus Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +6.11% | +1.32% | |
| Form 8-K Dianthus Therapeutics, For: Mar 09 | SEC filing · Form 8-K | SEC EDGAR | +6.11% | +1.32% | |
| Form S-8 Dianthus Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | +6.11% | +1.32% | |
| Dianthus Therapeutics to Host Conference Call and Webcast to Discuss the Interim Responder Analysis Results of the Phase 3 Captivate Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Press release | GlobeNewswire | +6.11% | +1.32% | |
| Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +2.59% | +6.13% | |
| Dianthus Therapeutics to Participate in The TD Cowen 46th Annual Health Care Conference | Press release | GlobeNewswire | +0.68% | -0.02% | |
| Dianthus Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 | Press release | GlobeNewswire | -2.30% | -2.78% | |
| Form EFFECT Dianthus Therapeutics, | SEC filing · Form EFFECT | SEC EDGAR | -0.04% | -0.13% | |
| Form S-3 Dianthus Therapeutics, | SEC filing · Form S-3 | SEC EDGAR | -0.41% | +2.99% | |
| Form 8-K Dianthus Therapeutics, For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | -2.06% | +2.14% | |
| Dianthus Therapeutics To Participate in the 44th Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | +0.18% | -6.96% | |
| Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE) | Press release | GlobeNewswire | +0.20% | -1.80% | |
| Dianthus Therapeutics To Participate in the 8th Annual Evercore Healthcare Conference | Press release | GlobeNewswire | +1.40% | +3.98% | |
| Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results | Press release | GlobeNewswire | +2.51% | +7.62% | |
| Form 10-Q Dianthus Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +2.51% | +7.62% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the DNTH section they belong to.
Where else DNTH is measured.
DNTH earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Dianthus Therapeutics, Inc.'s median reaction calculated?
Every labeled DNTH news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 274 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 59% of DNTH's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does DNTH's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.